Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
AAPL$329.82-6.69(-1.98%)Apple Readies Launch of AI-Powered Health App7:42:21 PM ETAMGN$456.00-4.12(-0.89%)Amgen (AMGN) Reports Q3 Earnings: What Key Metrics Have to Say7:30:56 PM ETAAPL$329.82-6.69(-1.98%)Apple: 3 Key Takeaways for Long-Term Investors7:28:50 PM ETAMD$508.30+17.47(+3.75%)Here's why AMD's stock is rising — and sending a confident message about the AI trade7:17:00 PM ETAMD$508.30+17.47(+3.75%)AMD: Expensive For A Reason7:15:26 PM ETGOOG$276.96-1.04(-0.37%)Google responds to political backlash over removing search from schools that ban AI7:10:07 PM ETPLTR$172.60-2.96(-1.66%)Jim Cramer Says the Executioner Is “Axing Palantir and Apple.” What Investors Should Make of It7:09:17 PM ETABBV$285.06-2.88(-1.00%)AbbVie expands Oxford R&D facility as part of £120 million-plus investment7:08:52 PM ETTSLA$391.23-12.63(-3.13%)Tesla misled South Korean customers about automated-driving tech, consumer group alleges7:03:18 PM ETABBV$285.06-2.88(-1.00%)AbbVie expands Oxford R&D facility as part of £120 million-plus investment7:01:03 PM ETAMD$508.30+17.47(+3.75%)Advanced Micro (AMD) Reports Q3 Earnings: What Key Metrics Have to Say7:01:02 PM ETAMD$508.30+17.47(+3.75%)UPDATE 7-AMD forecast eases AI spending fears as data-center sales surge7:00:54 PM ETAMD$508.30+17.47(+3.75%)AMD: The Odds Are Getting Better, But The Bet Still Isn't Worth It (Upgrade)7:00:06 PM ETHSBC$84.63-1.42(-1.65%)HSBC Holdings: 3 Key Takeaways for Long-Term Investors7:00:02 PM ETAMD$508.30+17.47(+3.75%)Advanced Micro Devices (AMD) Q3 Earnings and Revenues Top Estimates6:51:30 PM ETDIS$114.07+1.04(+0.92%)Why Walt Disney (DIS) Outpaced the Stock Market Today6:46:07 PM ETHD$332.32-7.52(-2.20%)Home Depot (HD) Stock Falls Amid Market Uptick: What Investors Need to Know6:46:05 PM ETAMD$508.30+17.47(+3.75%)AMD Q3: Profits Are Booming, Cash Is Disappearing (Rating Downgrade)6:45:12 PM ETCRWD$243.44+2.90(+1.20%)CrowdStrike's new kill switch can stop rogue AI agents in their tracks, CEO says6:37:07 PM ETAMD$508.30+17.47(+3.75%)AMD Soars After Huge Guidance News6:30:29 PM ETAMGN$456.00-4.12(-0.89%)Amgen (AMGN) Tops Q3 Earnings and Revenue Estimates6:15:56 PM ETANET$186.00+5.79(+3.53%)Arista Networks (ANET) Q3 Earnings and Revenues Beat Estimates6:15:53 PM ETAMD$508.30+17.47(+3.75%)AMD: Don't Chase The Record Quarter6:10:20 PM ETAMD$508.30+17.47(+3.75%)BRIEF-AMD CEO - Now Expect Revenue to Grow More Than 80% in 20276:02:02 PM ET

DNLI · NASDAQ

Denali Therapeutics Inc.

$20.70 +1.84 (+9.73%)

Company overview

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. Its lead product candidate is BIIB122/DNL151, a leucine-rich repeat kinase 2 (LRRK2) inhibitor small molecule currently in Phase I and Phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310, in Phase I/II clinical trials for Hunter syndrome; DNL343, in Phase I clinical trial for amyotrophic lateral sclerosis (ALS); AR443820/DNL788, which completed a Phase I clinical trial for ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, in Phase II clinical trial for cutaneous lupus erythematosus.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$3.3B
Employees
443
Headquarters
South San Francisco, CA
Website
denalitherapeutics.com
CEO
Ryan J. Watts
Listed
December 8, 2017
P/E
-7.19
Dividend yield
0.00%

Company financials

Revenue
$0.00
Gross profit
-$5.7M
Operating income
-$547M
EBITDA
-$524M
Net income
-$508M
EPS
-$2.88
Total assets
$1.3B
Total debt
$40M
Earnings yield
-13.91%

Revenue segmentation

By product (FY 2020)
By region (FY 2020)

No geographic segmentation.

Showing FY 2020

Price chart

16.9319.6222.3125.0127.70
DNLI 1D NASDAQ O19.11H19.20L18.32C18.86-0.08 (-0.42%)Vol1.24M

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
DNLIDenali Therapeutics Inc. Stock news Denali Therapeutics Q3 Earnings Call Highlights MarketBeat
DNLIDenali Therapeutics Inc. Stock news Denali Therapeutics Inc. (DNLI) Reports Q3 Loss, Beats Revenue Estimates Zacks Investment Research
DNLIDenali Therapeutics Inc. Stock news Denali Therapeutics swings to Q3 net profit on one-time gain Reuters
DNLIDenali Therapeutics Inc. Stock news BRIEF-Denali Therapeutics Q3 Net Income USD 70.126 Million Reuters
DNLIDenali Therapeutics Inc. Press release Denali Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights GlobeNewswire
DNLIDenali Therapeutics Inc. Press release Denali Therapeutics Receives 2026 Prix Galien USA Award for AVLAYAH® (tividenofusp alfa-eknm) as Best Biotechnology Product GlobeNewswire
DNLIDenali Therapeutics Inc. Press release Denali Therapeutics to Report Third Quarter 2026 Financial Results and Business Highlights on November 3, 2026 GlobeNewswire
DNLIDenali Therapeutics Inc. Stock news Critical Survey: Denali Therapeutics (NASDAQ:DNLI) vs. Altimmune (NASDAQ:ALT) Defense World
DNLIDenali Therapeutics Inc. Stock news Denali Therapeutics Inc. (DNLI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Seeking Alpha
DNLIDenali Therapeutics Inc. Stock news DNLI Stock Gains 33.1% in Three Months: Buy, Sell or Hold the Stock? Zacks Investment Research
DNLIDenali Therapeutics Inc. Stock news Denali Therapeutics: Bullish On Avlayah And Their Prospects Seeking Alpha
DNLIDenali Therapeutics Inc. Stock news Denali Therapeutics: AVLAYAH Converts A Platform Story Into A Commercial One Seeking Alpha
DNLIDenali Therapeutics Inc. Stock news Baillie Gifford Trims Denali Therapeutics (DNLI) Stake in June Reduction GuruFocus
DNLIDenali Therapeutics Inc. Stock news DNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum Zacks Investment Research
DNLIDenali Therapeutics Inc. Stock news Denali Therapeutics Inc. (DNLI) Q2 2026 Earnings Call Transcript Seeking Alpha
DNLIDenali Therapeutics Inc. Stock news Denali Therapeutics Q2 Earnings Call Highlights MarketBeat
DNLIDenali Therapeutics Inc. Stock news Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue Estimates Zacks Investment Research
DNLIDenali Therapeutics Inc. Press release Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026 GlobeNewswire
DNLIDenali Therapeutics Inc. Stock news Will Recent Setbacks Impact Growth Prospects of DNLI Stock? Zacks Investment Research
DNLIDenali Therapeutics Inc. Press release Denali Therapeutics to Give Opening Plenary Address at Alzheimer's Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier GlobeNewswire
See more
FAQ

Questions about Denali Therapeutics Inc.

What does Denali Therapeutics Inc. do?
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. Its lead product candidate is BIIB122/DNL151, a leucine-rich repeat kinase 2 (LRRK2) inhibitor small molecule currently in Phase I and Phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310, in Phase I/II clinical trials for Hunter syndrome; DNL343, in Phase I clinical trial for amyotrophic lateral sclerosis (ALS); AR443820/DNL788, which completed a Phase I clinical trial for ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, in Phase II clinical trial for cutaneous lupus erythematosus.
What is DNLI's market cap?
Denali Therapeutics Inc. (DNLI) is a listed stock with a live quote. The latest market cap on this page is $3.3B.
Where is Denali Therapeutics Inc. headquartered?
Denali Therapeutics Inc. is headquartered in South San Francisco, CA.
How do I get DNLI news from the API?
Call GET /v1/news?tickers=DNLI. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does DNLI news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for DNLI, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the DNLI price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs